Surgical Site Infection Control Market 2019 Global Analysis, Segments, SizePosted by Sapana on November 9th, 2019 Market Research Future published a half-cooked research report on the Surgical Site Infection Control Market Research Report - Global Forecast till 2023. Surgical Site Infection Control Market Insight The surgical site infection control market is growing pervasively over the past few years. Rising prevalence of hospital-acquired infections (HAI) and the most common types of HAI, such as surgical site infections and bloodstream infection (BSI) are expected to drive the market growth predominantly. Surgical site infections (SSI) are critical and sometimes are dangerous, too, which can cost hugely, resulting in higher mortality rates each year. In such a scenario, surgical site infection control becomes crucial. As a result, the surgical site infection control market is witnessing a rising demand. According to Market Research Future (MRFR), the global surgical site infection control market can impressively grow and attain a CAGR of 6.7% during the forecast period of 2018 to 2023. Avail Free Sample Copy at https://www.marketresearchfuture.com/sample_request/7830 Wide-spreading awareness of this kind of infection and the availability of novel medications & treatment procedures can propel the growth of the market. Also, improving economic conditions worldwide fuel market growth, enabling access to improved healthcare. Moreover, technological advances in medical science backed by the substantial investments made in the R&D activities foster market growth excellently. Conversely, unmet clinical needs alongside the incidents of drug resistance, complications, and side effects occurring during treatments are some of the factors expected to impede the market growth during the forecast period. Nevertheless, increasing government support for research & development would support the growth of the surgical site infection control market. Surgical Site Infection Control Market - Segments The market report has five dynamics to widen the scope of understanding, By Product: Manual Reprocessors Solution, Disinfectants (Hand Disinfectants, Skin Disinfectants, Surgical Scrubs, Surgical Drapes, Skin Preparation Solution, Medical Nonwovens, Surgical Gloves, others), and others. By Procedure: Cataract Surgery, Cesarean Section, Dental Restoration, Gastric Bypass, and others. By Type of Infection: Superficial Incisional SSI, Deep Incisional SSI, Organ or Space SSI, and others. By End-user: Ambulatory Surgical Centers, Hospitals, and others. By Regions: North America, Europe, APAC, and the Rest-of-the-World (RoW). Global Surgical Site Infection Control Market - Regional analysis North America dominates the global surgical site infection control market. The presence of well-established healthcare sectors in the region drives the growth of the regional market. Rising number of surgeries and increasing awareness regarding the healthcare management can foster the growth of the market. Moreover, comprehensive insurance coverage and the expansion of the private healthcare sector impact the market growth positively, improving overall healthcare infrastructure. The US and Canada account for the largest share in the surgical site infection control market in the region due to the rising patient population and increasing prevalence of SSI. Furthermore, high per capita health care expenditures and growing investments in R&D to develop new techniques to cure surgical site infection control act as major growth drivers. Europe stands second in the global surgical site infection control market. Increasing awareness of hygiene & sanitation, government support for high degree infection prevention programs, and formulation of various initiatives by NGO & Government to increase the awareness drive the regional market growth. The emergence of technologically advanced medical products, intense healthcare penetration, the availability of advanced treatment facilities, and skilled medical professionals can act as major thrust providers for the market. The Asia Pacific surgical site infection control market is rising rapidly. The vast population and the availability of low-cost medications & procedures to treat the surgical site infection control foster regional market growth. Furthermore, the burgeoning healthcare sector in the region, along with the high unmet needs, would provide impetus to the regional market growth over the forecast period. The Asia Pacific demonstrates a vast market potential with its warm weather favorable for the growth of various kinds of infections. Consequently, governments across the countries around the region have taken various efforts to improve healthcare services and provide better infrastructure. India and China are the leading markets in the region, followed by South Korea. Global Surgical Site Infection Control Market - Competitive Analysis Highly competitive, the surgical site infection control market appears to be fragmented, characterized by the presence of several well-established players. To gain a significant market share, players incorporate strategic initiatives such as mergers & acquisitions, collaborations, expansion, and new therapeutics & technology launch. They invest heavily in R&D and clinical trials to develop effective drugs, focusing on areas with a high unmet medical need, these companies assess areas that require further innovation over the progress that has been made. Substantial investments made by the top players to develop novel therapeutics for these infections, help these players to hold significant market share. Major Players: Players leading the global surgical site infection control market, include 3M, Becton Dickinson and Company, Belimed AG, bioMerieux SA, Getinge Group, Johnson & Johnson, Kimberly-Clark Corporation, Sotera Health, Ansell Limited, Steris Corporation, Lac-Mac Limited, Pacon Manufacturing Corp, and American Polyfilm Inc., among others. Browse Complete Report with TOC at https://www.marketresearchfuture.com/reports/surgical-site-infection-control-market-7830 Industry/Innovations/Related News: October 11, 2019 ---- 3M, an American multinational conglomerate operating in the fields of industry, worker safety, health care, and consumer goods, announced the completion of Acelity L.P. Inc. (the US), a medical device company and its KCI subsidiaries worldwide. Acelity is one of the leading medical technology company globally. The acquisition worth approximately USD 6.7 BN would further accelerate 3M’s role as a leader in treating advanced wound care, which is a significant and growing market segment. Recently, on May 16, 2019, had announced receiving the FDA approval for its PREVENA negative pressure incision management system indicated to help with reducing superficial surgical site infections in those at high risk of post-op infections. October 22, 2019 ---- Becton, Dickinson and Company India, a leading medical technology company conducted a program 'Heal-o-nomics' conceptualized to apprehend the challenges in preventing hospital-acquired infections (HAIs) to achieve better health outcomes at optimized cost, Including the most common types such as surgical site infections, and bloodstream infection (BSI). Presented studies include the epidemiology and prevention of BSI and the evaluation rates device-associated infections across Indian hospitals. The rising number of HAI in India has led experts to gather and discuss the ways to prevent them. Like it? Share it!More by this author |